Weekly Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings as of May 17, 2018

May 17, 2018 - By Norman Soto

During Q4 2017 the big money sentiment decreased to 0.98. That’s change of 0.31, from 2017Q3’s 1.29. 20 investors sold all, 70 reduced holdings as Integra LifeSciences Holdings Corporation ratio is negative. 65 rose positions while 23 funds bought positions. Funds hold 70.22 million shares thus 2.95% more from 2017Q3’s 68.21 million shares.
Conestoga Advisors Limited Company owns 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 5,000 shs. Burney holds 5,850 shs or 0.02% of its capital. Huntington State Bank, Ohio-based fund reported 2,129 shs. Sei Invs Commerce reported 184,244 shs or 0.03% of all its holdings. Louisiana State Employees Retirement Systems holds 0.06% or 27,300 shs in its capital. Prudential, a New Jersey-based fund reported 107,006 shs. Glenmede Na stated it has 1.09 million shs or 0.22% of all its holdings. Northern Corp stated it has 0.01% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Bancorporation Of Montreal Can owns 9,279 shs. Massachusetts Fin Service Com Ma invested 0.01% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Alliancebernstein Ltd Partnership has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Metropolitan Life Com New York holds 0.01% or 20,459 shs. Profund Advsrs Limited Company invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). California State Teachers Retirement accumulated 0.01% or 100,307 shs. Fdx Advsrs accumulated 7,622 shs.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

In total 9 analysts cover Integra Lifesciences (NASDAQ:IART). “Buy” rating has 3, “Sell” are 0, while 6 are “Hold”. 33% are bullish. 10 are the (NASDAQ:IART)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Wednesday, April 25 the firm has “Hold” rating given by Cantor Fitzgerald. On Thursday, March 29 the company was maintained by Oppenheimer. On Tuesday, January 2 the firm has “Neutral” rating by Bank of America given. On Wednesday, February 28 the rating was maintained by JMP Securities with “Market Outperform”. On Tuesday, January 2 the firm has “Market Perform” rating by Raymond James given. On Wednesday, April 11 the company was maintained by JP Morgan. On Wednesday, April 25 Jefferies maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) with “Buy” rating. On Thursday, April 26 the company was maintained by JP Morgan. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain
08/01/2018 Broker: Barclays Capital Rating: Hold New Target: $53.0
02/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $55 Downgrade
02/01/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

IART is touching $63.85 during the last trading session, after increased 1.04%.Integra LifeSciences Holdings Corporation is uptrending after having risen 29.35% since May 17, 2017. IART has 666,578 volume or 5.58% up from normal. IART outperformed the S&P 500 by 17.80%.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The firm is valued at $5.23 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.The P/E ratio is 77.87. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

A couple more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were posted by: Globenewswire.com which released on May 17, 2018 “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …”, also Globenewswire.com on May 09, 2018 posted “Integra LifeSciences Announces Proposed Public Offering of Common Stock”, the next Globenewswire.com is “Integra LifeSciences Prices Public Offering of Common Stock” on May 09, 2018. Globenewswire.com has article titled “Integra LifeSciences Reports First Quarter 2018 Financial Results”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.